The anticomplement immunofluorescence (ACIF) test was compared with the fluorescent antibody-to-membrane antigen (FAMA) test for determining varicella-zoster virus antibody levels as a measure of varicella-zoster virus immunity status. The ACIF test was found to be comparable to the FAMA test in sensitivity and could be used for examining sera at low dilutions of 1:2 and 1:4. In addition, the ACIF method proved to be a more economical procedure in terms of antigen required and personnel time necessary to perform the test. Heterologous varicellazoster virus antibody titer rises were demonstrated by the FAMA test with 10 serum pairs from patients with clinically diagnosed genital herpes simplex virus infection, indicating that the FAMA test is no more suitable than other serological methods for serodifferentiation of those herpes simplex virus and varicella-zoster virus infections in which antibody increases occur to both antigens.
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Varicella-zoster virus (VZV) infection in newborns and in immunocompromised individuals can be life threatening (4, 6) , and various preventive measures have been developed to protect these high-risk groups, including isolation of the patient and administration of zoster immune globulin (3, 8) . In addition, the usefulness of therapeutic agents such as adenine arabinoside, acyclovir, and interferon is presently being evaluated in clinical trials. Sensitive 20  21  22  23  24  25  26  27  28  29   CF   <8   QNS  <8  <8  <8  <8  <8  <8  <8  <8  QNS  <8  <8  <8  <8  <8  <8  <8  <8  <8  <8  <8  <8  <8  <8  <8  <8  <8  <8   Antibody titer by:   ACIF  FAMA   <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  <2  2  8  8  8  8  8  8  32  8  8  8  8  32  32  32  32  128  32  128  32  128  32  128  128  128  128  128  128  128  128  128  128  2128 (12) .
It was reported that the FAMA test did not demonstrate antibody titer rises to VZV in patients with HSV infection (13), but it was not indicated whether the HSV-infected patients examined were those in whom heterologous VZV antibody titer rises were demonstrable by the CF test or some other antibody assay. The present study clearly showed that FAMA test titer rises to VZV did occur in HSV-infected patients who showed heterotypic antibody titer rises by the CF and ACIF tests. These were young adults with genital HSV infections, in whom clinical symptoms were quite distinct from those of varicella-or herpes-zoster, and thus the possibility of dual HSV and VZV infection would be extremely unlkely. 
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